RedHill Biopharma Ltd. (RDHL) Financial Ratios
14 years of historical data (2011–2024) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 0.99
30Y Low1.0·High1.0
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 26.22
30Y Low4.0·High42.5
ROE
↑
N/A
—
5yr avg: 30.0%
30Y Low-206%·High-48%
Debt/EBITDA
N/A
—
5yr avg: 0.08
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RDHL Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
RedHill Biopharma Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $15M | $19M | $17M | $240M | $589M | $360M | $257M | $182M | $269M | $288M |
| Enterprise Value | $903014 | $11M | $15M | $120M | $298M | $646M | $335M | $228M | $165M | $216M | $266M |
| P/E Ratio → | -0.14 | — | 0.79 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.64 | 1.90 | 2.90 | 0.28 | 2.80 | 9.15 | 57.30 | 30.70 | 45.30 | 2667.82 | 95921.65 |
| P/B Ratio | — | — | 9.14 | — | 27.05 | 42.46 | 6.01 | 5.01 | 4.03 | 4.30 | 4.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RDHL EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.37 | 2.22 | 1.94 | 3.48 | 10.04 | 53.29 | 27.23 | 41.19 | 2135.28 | 88749.65 |
| EV / EBITDA | — | — | 0.99 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 0.60 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RDHL Profitability
Margins and return-on-capital ratios measuring operating efficiency
RedHill Biopharma Ltd. earns an operating margin of -181.7%. Operating margins have compressed from -69.3% to -181.7% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 47.0% | 46.1% | 42.4% | 42.7% | 64.1% | 66.1% | 46.9% | -30140.6% | -733300.0% |
| Operating Margin | -181.7% | -181.7% | 193.4% | -69.3% | -94.6% | -99.0% | -686.7% | -470.5% | -1297.0% | -30240.6% | -733400.0% |
| Net Profit Margin | -102.8% | -102.8% | 366.2% | -116.0% | -114.0% | -118.4% | -672.5% | -464.4% | -1136.6% | -29079.2% | -703000.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | 1155.9% | — | -859.7% | -206.2% | -76.1% | -80.7% | -84.5% | -47.8% | -49.6% |
| ROA | -40.2% | -40.2% | 26.3% | -42.2% | -54.1% | -59.9% | -62.0% | -64.8% | -69.2% | -41.6% | -44.1% |
| ROIC | — | — | 36.4% | -52.9% | -87.8% | -89.9% | -113.7% | -116.2% | -207.7% | -96.5% | -57.2% |
| ROCE | — | — | 332.0% | -140.2% | -78.5% | -74.7% | -74.8% | -80.6% | -90.9% | -46.9% | -49.8% |
RDHL Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $356000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.57 | — | 9.89 | 6.27 | 0.06 | — | — | — | — |
| Debt / EBITDA | — | — | 0.08 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -2.12 | — | 6.57 | 4.16 | -0.42 | -0.57 | -0.37 | -0.86 | -0.36 |
| Net Debt / EBITDA | — | — | -0.30 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -265.69 | -265.69 | 34.42 | -1.04 | -4.90 | -5.12 | -98.31 | -235.51 | -674.96 | -4363.29 | -1833.50 |
Net cash position: cash ($5M) exceeds total debt ($356000)
RDHL Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.54x is below 1.0, meaning current liabilities exceed current assets. The current ratio has improved from 0.44x to 0.54x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.54 | 0.54 | 0.84 | 0.44 | 1.09 | 0.96 | 5.01 | 5.47 | 4.37 | 12.66 | 10.97 |
| Quick Ratio | 0.37 | 0.37 | 0.61 | 0.38 | 0.91 | 0.87 | 4.84 | 5.40 | 4.31 | 12.45 | 17.23 |
| Cash Ratio | 0.21 | 0.21 | 0.33 | 0.10 | 0.47 | 0.41 | 4.51 | 5.12 | 3.91 | 12.35 | 10.54 |
| Asset Turnover | — | 0.45 | 0.28 | 0.39 | 0.47 | 0.36 | 0.08 | 0.13 | 0.07 | 0.00 | 0.00 |
| Inventory Turnover | 0.87 | 0.87 | 0.79 | 3.03 | 3.34 | 5.65 | 1.20 | 3.69 | 3.26 | 27.42 | — |
| Days Sales Outstanding | — | 161.83 | 183.62 | 223.70 | 138.43 | 166.11 | 94.86 | 60.91 | 206.05 | 1778.02 | 26766.67 |
RDHL Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
RedHill Biopharma Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 126.0% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $518244 | $123858 | $93054 | $72854 | $59384 | $46240 | $35314 | $25760 | $22342 |
Peer Comparison
Compare RDHL with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RDHLYou | $5M | -0.1 | — | — | 60.3% | -181.7% | — | — | — |
 CMPX | $250M | -4.3 | — | — | — | — | -41.3% | -41.3% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 IRWD | $680M | 27.8 | 8.8 | 5.4 | 99.4% | 40.1% | — | 54.0% | 5.0 |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 MNKD | $1B | 177.5 | 29.3 | 80.1 | 82.5% | 11.1% | — | 21.6% | 9.3 |
 TLRY | $660M | -0.2 | — | — | 29.3% | -277.9% | -89.1% | -66.2% | — |
 MCK | $92B | 29.2 | 18.7 | 17.6 | 3.5% | 1.2% | — | 540.6% | 1.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See RDHL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RDHL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RDHL vs CMPX
Side-by-side business, growth, and profitability comparison vs Compass Therapeutics, Inc..
Start ComparisonRDHL — Frequently Asked Questions
Quick answers to the most common questions about buying RDHL stock.
What is RedHill Biopharma Ltd.'s P/E ratio?
RedHill Biopharma Ltd.'s current P/E ratio is -0.1x. The historical average is 0.8x.
Is RDHL stock overvalued?
Based on historical data, RedHill Biopharma Ltd. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
What are RedHill Biopharma Ltd.'s profit margins?
RedHill Biopharma Ltd. has 60.3% gross margin and -181.7% operating margin.